Anna-Maria D.
- Country
- Germany
- Department
- Pediatric Pneumology, Allergology and Neonatology
Research Overview
- Evaluation of Long-term Safety and Efficacy of Tezacaftor, Deutivacaftor, and Vanzacaftor Combination Therapy in Patients with Cystic Fibrosis
- Long-term Safety and Efficacy Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients Aged 12 Months and Older
- Long-term Safety and Efficacy Evaluation of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients with Non-F508del CFTR Genotypes
Data & Insights
Has run more than one trial at 54 of 101 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in the treatment of cystic fibrosis, with particular emphasis on innovative therapeutic approaches for patients across different age groups, from infants to adults.
- CFTR Modulator Therapies
- Pediatric Respiratory Care
- Long-term Disease Management
Their research interests focus on evaluating novel combination treatments for enhancing respiratory function in cystic fibrosis patients.
Therapeutic Innovation
The investigator's work centers on assessing advanced combination therapies including elexacaftor, tezacaftor, and ivacaftor compounds, as well as newer agents like vanzacaftor and deutivacaftor.
- Novel Drug Combinations
- Treatment Safety Profiles
- Clinical Efficacy Studies
Their research encompasses comprehensive evaluation of therapeutic interventions across various patient populations.
Pediatric Research
The investigator demonstrates particular expertise in early intervention treatments for young patients, conducting studies in age groups ranging from 12 months to 11 years.
- Early-Age Interventions
- Developmental Considerations
- Age-Specific Treatment Protocols
Their work includes careful assessment of treatment tolerability and safety in pediatric populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.